MX2015015290A - Compuestos furanona como inhibidores de quinasa. - Google Patents
Compuestos furanona como inhibidores de quinasa.Info
- Publication number
- MX2015015290A MX2015015290A MX2015015290A MX2015015290A MX2015015290A MX 2015015290 A MX2015015290 A MX 2015015290A MX 2015015290 A MX2015015290 A MX 2015015290A MX 2015015290 A MX2015015290 A MX 2015015290A MX 2015015290 A MX2015015290 A MX 2015015290A
- Authority
- MX
- Mexico
- Prior art keywords
- furanone compounds
- kinase inhibitors
- compounds
- treatment
- furanone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
Abstract
La presente invención provee compuestos furanona novedosos, o sales farmacéuticamente aceptables, solvatos o profármacos de los mismos, como inhibidores de Raf quinasa, especialmente de BRAF quinasa, que son agentes terapéuticos útiles para el tratamiento de enfermedades o trastornos relacionados con Raf quinasa tales como melanomas, cánceres y leucemia. La invención también provee métodos y procesos para preparar estos compuestos furanona novedosos, composiciones farmacéuticas que contienen estos compuestos furanona y métodos de tratamiento que usan estos compuestos furanona.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361820853P | 2013-05-08 | 2013-05-08 | |
PCT/US2014/037247 WO2014182873A1 (en) | 2013-05-08 | 2014-05-08 | Furanone compounds as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015015290A true MX2015015290A (es) | 2016-02-22 |
Family
ID=51867735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015015290A MX2015015290A (es) | 2013-05-08 | 2014-05-08 | Compuestos furanona como inhibidores de quinasa. |
Country Status (9)
Country | Link |
---|---|
US (1) | US9458140B2 (es) |
EP (1) | EP2994127B1 (es) |
CN (1) | CN105163733B (es) |
AU (1) | AU2014262658B2 (es) |
CA (1) | CA2909578C (es) |
HK (1) | HK1217654A1 (es) |
MX (1) | MX2015015290A (es) |
TW (1) | TWI634114B (es) |
WO (1) | WO2014182873A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2722667C2 (ru) * | 2016-03-10 | 2020-06-02 | Лутрис Фарма Лтд. | Использование ингибиторов braf для лечения кожных реакций |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020124397A1 (en) * | 2018-12-19 | 2020-06-25 | Inventisbio Shanghai Ltd. | C-terminal src kinase inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4606756A (en) * | 1984-10-26 | 1986-08-19 | Chevron Research Company | Herbicidal 2-(nitrogen heterocycle)5-amino-3-oxo-4-(substituted-phenyl)-2,3-dihydrofurans |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
KR0119908B1 (ko) * | 1994-04-18 | 1997-10-30 | 강박광 | 3(2h)-푸란온 유도체 |
TR200102958T2 (tr) * | 1999-04-14 | 2002-05-21 | Pacific Corporation | Siklooksijenaz-2 inhibitörleri olarak 4,5-diaril-3(2H)-furanon türevleri. |
EP2121669A2 (en) * | 2007-01-30 | 2009-11-25 | Biogen Idec MA, Inc. | Furanone compounds and methods of making and using the same |
UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
KR20110031355A (ko) * | 2008-06-25 | 2011-03-25 | 엔비보 파마슈티칼즈, 인코퍼레이티드 | 1,2―이치환된 헤테로사이클릭 화합물 |
CN102459242B (zh) * | 2009-05-07 | 2015-08-26 | 费瑞姆医药有限公司 | 苯氧基甲基杂环化合物 |
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
TW201512201A (zh) * | 2013-03-14 | 2015-04-01 | Forum Pharmaceuticals Inc | 化合物的多晶型及鹽類 |
-
2014
- 2014-05-07 TW TW103116311A patent/TWI634114B/zh active
- 2014-05-08 CA CA2909578A patent/CA2909578C/en active Active
- 2014-05-08 WO PCT/US2014/037247 patent/WO2014182873A1/en active Application Filing
- 2014-05-08 US US14/889,507 patent/US9458140B2/en active Active
- 2014-05-08 MX MX2015015290A patent/MX2015015290A/es active IP Right Grant
- 2014-05-08 AU AU2014262658A patent/AU2014262658B2/en active Active
- 2014-05-08 CN CN201480024052.0A patent/CN105163733B/zh active Active
- 2014-05-08 EP EP14795255.0A patent/EP2994127B1/en active Active
-
2016
- 2016-05-20 HK HK16105768.1A patent/HK1217654A1/zh unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2722667C2 (ru) * | 2016-03-10 | 2020-06-02 | Лутрис Фарма Лтд. | Использование ингибиторов braf для лечения кожных реакций |
Also Published As
Publication number | Publication date |
---|---|
TWI634114B (zh) | 2018-09-01 |
CN105163733B (zh) | 2019-05-31 |
EP2994127A4 (en) | 2016-12-14 |
CA2909578C (en) | 2021-07-06 |
EP2994127A1 (en) | 2016-03-16 |
WO2014182873A1 (en) | 2014-11-13 |
TW201506021A (zh) | 2015-02-16 |
AU2014262658B2 (en) | 2018-08-02 |
US20160096825A1 (en) | 2016-04-07 |
HK1217654A1 (zh) | 2017-01-20 |
EP2994127B1 (en) | 2019-10-09 |
CN105163733A (zh) | 2015-12-16 |
AU2014262658A1 (en) | 2015-11-05 |
CA2909578A1 (en) | 2014-11-13 |
US9458140B2 (en) | 2016-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500367A1 (en) | Compounds that inhibit mcl-1 protein | |
PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
EA033689B9 (ru) | Ингибиторы g12c kras | |
PH12015502414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
MX2016009403A (es) | Compuestos heterociclicos. | |
PH12015502159A1 (en) | Chemical entities | |
TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
PH12019500568A1 (en) | Dopamine-b-hydroxylase inhibitors | |
MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. | |
NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
TR201819805T4 (tr) | Flavaglin türevleri̇. | |
MX2018007517A (es) | Compuestos triciclicos y composiciones como inhibidores de quinasa. | |
MX2015015290A (es) | Compuestos furanona como inhibidores de quinasa. | |
MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
TW201713630A (en) | Substituted quinazoline compounds and methods of use thereof | |
EA201600411A1 (ru) | Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний | |
MY192305A (en) | Bipyrazole derivatives as jak inhibitors | |
NZ747821A (en) | Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |